Pipeline

Initially focused on musculoskeletal indications, our current pipeline includes programs for pain associated with knee osteoarthritis, lateral hip pain, thumb joint pain, and migraine.

Scroll to explore the pipeline.

Reneurx development pipeline by indication and development phase.
Indication	Pre-ClinicalPilotPivotalCommercial Available
Pain Associated with Knee Osteoarthritis	Pivotal clinical development
Lateral Hip Pain	Pivotal clinical development
Carpometacarpal (thumb) joint	Pilot clinical development
Migraine Disorders	Pre-clinical development

Clinical Trials

A series of clinical studies are being conducted to evaluate the safety and effectiveness of Reneurx Nerve-Selective Therapy

Hip

Person holding their outer hip while seated.

Brixton is enrolling participants in the randomized, pivotal RENEU clinical trial evaluating the safety and effectiveness of Reneurx therapy for the management of chronic pain associated with the outer hip.

To qualify for RENEU, participants must meet the following eligibility criteria:

Be between the age of 22 and 80 years old
Experience outer hip pain on one or both hips
Tried conservative therapies in the past that no longer provide relief
Agree to see the study doctor for a 6 month follow up period, with the potential to be extended for 12 months

For additional information about trial, eligibility and trial locations, please visit: clinicaltrials.gov/study/NCT07568015.

Thumb

Brixton is conducting a pilot clinical study to evaluate the safety and effectiveness of Reneurx therapy in those with painful thumb basal joint arthritis.

To qualify, participants must meet the following eligibility criteria:

Age of 22 years and older
Have a diagnosis of carpometacarpal osteoarthritis
Experience moderate thumb pain associated with use
Have tried at least 6 months of other conservative treatments that no longer provide pain relief

For more information on the trial, eligibility, and trial locations, please contact: clinical@brixtonbio.com.